Carflizomib is Extraordinarily Active in Myeloma Mainstay drug for physicians and patients - 101931

Spotlight
Video

Carflizomib is Extraordinarily Active in Myeloma Mainstay drug for physicians and patients

ASHReport has 256 videos Subscribe Here

Loading........
Description: Robert Rifkin, MD from Rocky Mountain Cancer Center discusses Carflizomib is extraordinarily active in myeloma and mainstay drug for physicians and patients at the 2017 American Society of Hematology.
Shared By : ASHReport
Posted on : 01/23/18
Added : 9 months ago
Category : Multiple Myeloma